Global Bleeding Disorders Therapeutics Market 2020-2024 | Evolving Opportunities with Baxter International Inc. & Bayer AG | Technavio
LONDON--(BUSINESS WIRE)--Nov 11, 2019--
The global bleeding disorders therapeutics market size is poised to grow by USD 4.32 billion during 2020-2024, according to a new report by Technavio, progressing at a CAGR of close to 7% during the forecast period. Request Free Sample Pages
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005379/en/
Technavio has announced its latest market research report titled global bleeding disorders therapeutics market 2020-2024 (Graphic: Business Wire)
Read the 170-page research report with TOC on “Bleeding disorders therapeutics Market Analysis Report by Type (Hemophilia A, Hemophilia B, Von Willebrand disease, and Other disorders) and geography (North America, Europe, Asia, and ROW) 2020-2024”.
The market is driven by rising initiatives to increase awareness about bleeding disorders. Also, the emergence of gene therapy is anticipated to further boost the growth of the bleeding disorders therapeutics market.
The market is witnessing rising initiatives by public and private organizations and governments, to increase awareness about bleeding disorders. These actions and campaigns have created awareness about the advances and discoveries in medicine for bleeding disorders in recent years. Organizations such as the National Hemophilia Foundation, von Willebrand Education Network, and World Federation of Hemophilia support are engaged in creating awareness about bleeding disorders. Such awareness campaigns will have a significant impact on the growth of the market during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Bleeding Disorders Therapeutics Companies:
Baxter International Inc.
Baxter International Inc. has business operations in various segments, including renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, acute therapies, and other. The company’s key product offerings include FEIBA, HEMOFIL M, RIXUBIS, and Prothromplex TOTAL.
Bayer AG operates the business under various segments, namely pharmaceuticals, crop science, consumer health, and animal health. Some of the company’s key offerings include Jivi, KOVALTRY, and Kogenate FS.
CSL Ltd. manufactures, markets, and develops plasma therapies and conducts early-stage research on plasma and non-plasma therapies. The company’s key offerings in the bleeding disorders therapeutics market include Corifact, RiaSTAP, Stimate, Humate-P, AFSTYLA, IDELVION, and MONONINE.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. focuses on the development of drugs in the oncology, immunology, neuroscience, ophthalmology, and infectious diseases areas, as well as other therapeutic areas. The company offers HEMLIBRA, which is a prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
Grifols SA has business operations under various segments, which include bioscience, hospital, diagnostic, bio supplies, and others. The company’s key offerings include ALPHANATE, Profilnine SD, and AlphaNine SD.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform
Bleeding Disorders Therapeutics Type Outlook (Revenue, USD Million, 2020-2024)
Bleeding Disorders Therapeutics Regional Outlook (Revenue, USD Million, 2020-2024)
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report
Related Reports on Health Care are:
Hemophilia A Therapeutics Market – Hemophilia A Therapeutics Market by product (recombinant therapies, plasma-derived therapies, hormonal therapies, and others), type (on-demand treatment, prophylactic treatment, and inhibitor treatment) and geography (Americas, APAC, and EMEA).
Hematology Analyzers and Reagents Market – Hematology Analyzers and Reagents Market by end-users (hospitals and diagnostic centers, blood bank centers, and others) and geography (North America, Europe, Asia, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005379/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 11/11/2019 11:30 AM/DISC: 11/11/2019 11:30 AM